乌司他丁佐治重症肺炎临床评价

Clinical Efficacy of Ulinastatin in the Adjuvant Treatment of Patients with Severe Pneumonia

目的探讨乌司他丁佐治重症肺炎的临床疗效。方法选取医院2014年5月至2019年6月收治的重症肺炎患者3 074例,按治疗方法的不同分为对照组(2 727例)和研究组(347例)。两组患者均予营养支持、抗感染、呼吸支持、维持水电解质平衡等常规治疗,研究组患者加用乌司他丁注射液。结果研究组患者的血液p H、动脉血氧分压和氧合指数达标率均显著高于对照组(P <0.05),研究组患者重症监护室(ICU)入住率显著高于对照组(34.58%比9.90%,P <0.05),ICU住院天数明显短于对照组(P <0.05);研究组并发症发生率为6.63%,显著低于对照组的9.94%(P <0.05);两组不良反应发生率相当(P> 0.05)。结论乌司他丁佐治重症肺炎,可改善患者的血气指标,缩短ICU住院时间,减少并发症。

Objective To investigate the clinical efficacy of ulinastatin in the adjuvant treatment of patients with severe pneumonia.Methods A total of 3074 patients with severe pneumonia admitted to our hospital from May 2014 to June 2019 were selected and divided into the control group(2727 cases)and the study group(347 cases)according to the different treatment methods.The patients in the two groups were given routine treatment such as nutritional support,anti-infection,respiratory support,maintaining water and electrolyte balance,and the patients in the study group were additionally given Ulinastatin Injection.Results The blood p H value,arterial oxygen partial pressure and oxygenation indexes in the study group were significantly higher than those in the control group(P<0.05).The intensive care unit(ICU)hospitalization rate in the study group was significantly higher than that in the control group(34.58%vs.9.90%,P<0.05),and the ICU length of stay in the study group was significantly shorter than that in the control group(P<0.05).The incidence of complications in the study group was 6.63%,which was significantly lower than 9.94%in the control group(P<0.05).The incidence of adverse reactions was similar between the two groups(P>0.05).Conclusion Ulinastatin in the adjuvant treatment of severe pneumonia can improve the blood gas indexes,shorten the ICU length of stay and reduce complications.